Gut microbiome and microbial metabolites: a new system affecting metabolic disorders.

Diabetes Gut microbiome Metabolomics Metagenomics Obesity

Journal

Journal of endocrinological investigation
ISSN: 1720-8386
Titre abrégé: J Endocrinol Invest
Pays: Italy
ID NLM: 7806594

Informations de publication

Date de publication:
Sep 2019
Historique:
received: 17 12 2018
accepted: 12 02 2019
pubmed: 23 2 2019
medline: 25 1 2020
entrez: 22 2 2019
Statut: ppublish

Résumé

The gut microbiome is emerging as an important player in the field of metabolic disorders. Currently, several studies are ongoing to determine whether the effect of gut microbiome on obesity, type 2 diabetes, non-alcoholic fatty liver disease, and other metabolic diseases is determined by singular species or rather by a functional role of bacterial metabolism at higher taxonomical level. Deciphering if a single or more species are responsible for metabolic traits or rather microbial metabolic pathways are responsible for effects on host metabolism may help to identify appropriate dietary interventions to support microbial functions according to the prevalent host disease. Furthermore, the combination of metagenomics and metabolomics-based signature might be applied in the future to improve the risk prediction in healthy subjects. In this review, I will summarize the current findings regarding the role of gut microbiome and metabolites in metabolic disorders to argue whether the current achievements may be translated into clinical practice.

Identifiants

pubmed: 30788772
doi: 10.1007/s40618-019-01022-9
pii: 10.1007/s40618-019-01022-9
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1011-1018

Références

Proc Natl Acad Sci U S A. 2005 Aug 2;102(31):11070-5
pubmed: 16033867
Nature. 2006 Dec 21;444(7122):1022-3
pubmed: 17183309
Nature. 2006 Dec 21;444(7122):1027-31
pubmed: 17183312
Diabetes. 2007 Jul;56(7):1761-72
pubmed: 17456850
Diabetes. 2008 Jun;57(6):1470-81
pubmed: 18305141
Nature. 2009 Jan 22;457(7228):480-4
pubmed: 19043404
PLoS One. 2010 Feb 05;5(2):e9085
pubmed: 20140211
EMBO Mol Med. 2011 Sep;3(9):559-72
pubmed: 21735552
Gut. 2012 Apr;61(4):543-53
pubmed: 22110050
Diabetes. 2012 Feb;61(2):364-71
pubmed: 22190648
Nature. 2012 Oct 4;490(7418):55-60
pubmed: 23023125
Nat Commun. 2012;3:1245
pubmed: 23212374
Nature. 2013 Jun 6;498(7452):99-103
pubmed: 23719380
Nature. 2013 Aug 29;500(7464):541-6
pubmed: 23985870
Nature. 2013 Aug 29;500(7464):585-8
pubmed: 23985875
Science. 2013 Sep 6;341(6150):1241214
pubmed: 24009397
Immunity. 2014 Aug 21;41(2):296-310
pubmed: 25065623
Gut. 2015 Nov;64(11):1744-54
pubmed: 25500202
Endocr Connect. 2016 Jan;5(1):1-9
pubmed: 26555712
Nature. 2015 Dec 10;528(7581):262-266
pubmed: 26633628
Nat Rev Endocrinol. 2016 Mar;12(3):177-83
pubmed: 26775764
Nat Med. 2016 Apr;22(4):421-6
pubmed: 26950361
Mol Metab. 2016 Mar 28;5(6):392-403
pubmed: 27257599
Cell. 2016 Jun 2;165(6):1332-1345
pubmed: 27259147
Cell Metab. 2016 Jul 12;24(1):41-50
pubmed: 27320064
Nat Commun. 2016 Jun 28;7:12015
pubmed: 27352007
Cell Rep. 2016 Jul 19;16(3):731-43
pubmed: 27373162
Nature. 2016 Jul 06;535(7610):56-64
pubmed: 27383980
Nature. 2016 Jul 21;535(7612):376-81
pubmed: 27409811
Dig Dis. 2016;34 Suppl 1:11-8
pubmed: 27548822
MBio. 2016 Aug 23;7(4):
pubmed: 27555308
JAMA. 2017 Jan 24;317(4):355-356
pubmed: 28006047
J Endocrinol Invest. 2017 Jun;40(6):567-576
pubmed: 28063079
World J Gastroenterol. 2017 Feb 7;23(5):842-852
pubmed: 28223728
Obes Surg. 2017 May;27(5):1345-1357
pubmed: 28265960
Sci Rep. 2017 Apr 11;7:46337
pubmed: 28397877
Diabetologia. 2017 Jun;60(6):943-951
pubmed: 28434033
Nat Med. 2017 Jul;23(7):850-858
pubmed: 28530702
Nat Med. 2017 Jul;23(7):859-868
pubmed: 28628112
Nat Rev Gastroenterol Hepatol. 2017 Oct;14(10):573-584
pubmed: 28743984
Mol Nutr Food Res. 2018 Feb;62(3):
pubmed: 29105287
J Endocrinol Invest. 2018 May;41(5):509-521
pubmed: 29189999
Nat Rev Microbiol. 2018 Mar;16(3):171-181
pubmed: 29307889
BMJ. 2018 Jan 8;360:j5145
pubmed: 29311119
Benef Microbes. 2018 Apr 25;9(3):367-373
pubmed: 29482339
Nature. 2018 Mar 8;555(7695):210-215
pubmed: 29489753
Clin Sci (Lond). 2018 Mar 9;132(5):509-522
pubmed: 29523750
Circ Genom Precis Med. 2018 Apr;11(4):e002157
pubmed: 29572205
Science. 2018 Mar 9;359(6380):1151-1156
pubmed: 29590046
Nat Med. 2018 Apr 10;24(4):392-400
pubmed: 29634682
Diabetologia. 2018 Jul;61(7):1560-1571
pubmed: 29663011
Microbiome. 2018 May 1;6(1):81
pubmed: 29716650
J Endocrinol Invest. 2019 Feb;42(2):117-128
pubmed: 29730732
Nutr Diabetes. 2018 May 25;8(1):35
pubmed: 29795366
Gut. 2019 Jan;68(1):70-82
pubmed: 29899081
Nat Med. 2018 Jul;24(7):1070-1080
pubmed: 29942096
Nat Commun. 2018 Jul 9;9(1):2655
pubmed: 29985401
Gut. 2019 Jan;68(1):5-6
pubmed: 29991642
Cell Mol Gastroenterol Hepatol. 2018 Feb 15;6(2):149-162
pubmed: 30023411
Cell Mol Life Sci. 2018 Nov;75(21):3977-3990
pubmed: 30101405
Curr Diab Rep. 2018 Aug 15;18(10):76
pubmed: 30112615
J Exp Med. 2019 Jan 7;216(1):20-40
pubmed: 30322864

Auteurs

M Federici (M)

Department of Systems Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133, Rome, Italy. federicm@uniroma2.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH